X染色体在阿尔茨海默病遗传学中的作用
该研究对多个AD相关队列进行X染色体全关联研究荟萃分析,纳入1 152 284名欧洲血统非西班牙裔白人(含138 558例AD),发现6个独立位点达X染色体全显著,其中SLC9A7位点达全基因组显著(OR 1.03,95%CI 1.02-1.04)。
要点
- 首次大规模X染色体全关联研究鉴定出AD新位点SLC9A7。
- 6个位点达X染色体全显著,4个支持与附近基因表达连锁。
- SLC9A7位点达全基因组显著,并共定位SLC9A7与CHST7基因。
核心结论
- 该大型XWAS鉴定出新的SLC9A7位点,SLC9A7调节高尔基体分泌区室pH稳态,预计对β淀粉样蛋白蓄积有下游效应,研究增进了AD遗传学认识并可能提供新生物药物靶点,结果为阐明X染色体在AD性别差异中的作用提供了初步见解。
研究设计与样本
- 对来自美国阿尔茨海默病遗传学联盟、阿尔茨海默病测序计划、英国生物银行、芬兰健康登记处和美国百万退伍军人计划的病例对照、家系、人群和纵向AD相关队列的遗传关联研究进行荟萃分析。
- 通过病例对照逻辑回归分析评估AD风险,数据分析于2023年1月至2024年3月进行。
- 纳入高密度单核苷酸变异微阵列和全基因组测序的遗传数据及已发表研究的多组织表达和蛋白质数量性状位点汇总统计,以进行后续遗传共定位分析。
- 从转诊和志愿者样本中选择1 629 863名合格参与者,其中477 596人因分析排除标准被排除,原始研究中拒绝参与的人数不可获得。
主要发现
- 分析纳入1 152 284名非西班牙裔白人、欧洲血统参与者(664 403 [57.7%]女性,487 881 [42.3%]男性),包括138 558例AD个体。
- 6个独立遗传位点通过X染色体全显著(P < 1 × 10-5),其中4个显示AD遗传信号与脑和非脑组织中附近基因表达的连锁证据。
- 这4个位点中1个通过保守的全基因组显著(P < 5 × 10-8),其领先变异位于SLC9A7内含子(OR 1.03;95%CI 1.02-1.04),共定位分析优先考虑SLC9A7和邻近的CHST7基因。
- 这6个位点中4个显示关于AD风险的X染色体失活逃逸证据。
关键数值与推荐
- 关联在X染色体全(P < 1 × 10-5)和全基因组(P < 5 × 10-8)显著性水平上考虑。
- 主要分析为非分层分析,次要分析评估性别分层效应。
- SLC9A7领先变异OR 1.03(95%CI 1.02-1.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原始研究中拒绝参与的人数不可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The X chromosome has remained enigmatic in Alzheimer disease (AD), yet it makes up 5% of the genome and carries a high proportion of genes expressed in the brain, making it particularly appealing as a potential source of unexplored genetic variation in AD. OBJECTIVES: To perform the first large-scale X chromosome-wide association study (XWAS) of AD. DESIGN, SETTING, AND PARTICIPANTS: This was a meta-analysis of genetic association studies in case-control, family-based, population-based, and longitudinal AD-related cohorts from the US Alzheimer's Disease Genetics Consortium, the Alzheimer's Disease Sequencing Project, the UK Biobank, the Finnish health registry, and the US Million Veterans Program. Risk of AD was evaluated through case-control logistic regression analyses. Data were analyzed between January 2023 and March 2024. Genetic data available from high-density single-nucleotide variant microarrays and whole-genome sequencing and summary statistics for multitissue expression and protein quantitative trait loci available from published studies were included, enabling follow-up genetic colocalization analyses. A total of 1 629 863 eligible participants were selected from referred and volunteer samples, 477 596 of whom were excluded for analysis exclusion criteria. The number of participants who declined to participate in original studies was not available. MAIN OUTCOME AND MEASURES: Risk of AD, reported as odds ratios (ORs) with 95% CIs. Associations were considered at X chromosome-wide (P < 1 × 10-5) and genome-wide (P < 5 × 10-8) significance. Primary analyses are nonstratified, while secondary analyses evaluate sex-stratified effects. RESULTS: Analyses included 1 152 284 participants of non-Hispanic White, European ancestry (664 403 [57.7%] female and 487 881 [42.3%] male), including 138 558 individuals with AD. Six independent genetic loci passed X chromosome-wide significance, with 4 showing support for links between the genetic signal for AD and expression of nearby genes in brain and nonbrain tissues. One of these 4 loci passed conservative genome-wide significance, with its lead variant centered on an intron of SLC9A7 (OR, 1.03; 95% CI, 1.02-1.04) and colocalization analyses prioritizing both the SLC9A7 and nearby CHST7 genes. Of these 6 loci, 4 displayed evidence for escape from X chromosome inactivation with regard to AD risk. CONCLUSION AND RELEVANCE: This large-scale XWAS of AD identified the novel SLC9A7 locus. SLC9A7 regulates pH homeostasis in Golgi secretory compartments and is anticipated to have downstream effects on amyloid β accumulation. Overall, this study advances our knowledge of AD genetics and may provide novel biological drug targets. The results further provide initial insights into elucidating the role of the X chromosome in sex-based differences in AD.
引用
- Belloy ME, Le Guen Y, Stewart I, et al. Role of the X Chromosome in Alzheimer Disease Genetics. JAMA Neurol. 2024. PMID: 39250132. doi:10.1001/jamaneurol.2024.2843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。